Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
ConditionAdvanced or Metastatic Solid Tumors
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorInnate Pharma
About this trial
This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are known to express Nectin-4
Eligibility criteria
Qualifiers
Histologically confirmed, unresectable, locally advanced or metastatic solid tumors that are known to express Nectin-4
Prior systemic treatment for locally advanced or metastatic disease, yet no therapy with demonstrated clinical benefit for the tumor type is available.
Measurable disease according to RECIST 1.1.
Archival tumor tissue obtained within 4 months of screening and since the last anticancer therapy prior to the study or agree to undergo a tumor biopsy at baseline.
Disqualifiers
Known or suspected brain metastases.
Participants with an active infection, Any other infection requiring systemic treatment or latent infection.
Participants with clinically significant comorbidity(s).
History of treatment for, or suspicion or confirmed interstitial lung disease (ILD) at baseline.
Trial design
Treatments tested in this trial
- IPH4502
Treatment groups
145 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov